Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IMC-C103C

Other · developed by Immunocore

Phase 1/2 Most advanced trial (none active)
IMCR Developer
1 Registered trials

What is IMC-C103C?

IMC-C103C is an agent studied in select advanced solid tumors, given as a weekly subcutaneous injection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
Immunocore Ltd (IMCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03973333 Phase 1/2 Select Advanced Solid Tumors Withdrawn IMCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Select Advanced Solid Tumors

More from Immunocore

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IMCR page.

Follow IMCR, the company behind IMC-C103C

See IMCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.